Department of Viral Diarrhea, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control, Beijing, China.
Vaccine. 2012 Nov 6;30(48):6940-5. doi: 10.1016/j.vaccine.2012.05.084. Epub 2012 Jun 15.
Two rotavirus vaccines have been licensed globally since 2006. In China, only a lamb rotavirus vaccine is licensed and several new rotavirus vaccines are in development. Data regarding the projected health impact and cost-effectiveness of vaccination of children in China against rotavirus will assist policy makers in developing recommendations for vaccination.
Using a Microsoft Excel model, we compared the national health and economic burden of rotavirus disease in China with and without a vaccination program. Model inputs included 2007 data on burden and cost of rotavirus outcomes (deaths, hospitalizations, outpatient visits), projected vaccine efficacy, coverage, and cost. Cost-effectiveness was measured in US dollars per disability-adjusted life-year (DALY) and US dollars per life saved.
A 2-dose rotavirus vaccination program could annually avert 3013 (62%) deaths, 194,794 (59%) hospitalizations and 1,333,356 (51%) outpatient visits associated with rotavirus disease in China. The medical break-even price of the vaccine is $1.19 per dose. From a societal perspective, a vaccination program would be highly cost-effective in China at the vaccine price of $2.50 to $5 per dose, and be cost-effective at the price of $10 to $20 per dose.
A national rotavirus vaccination program could be a cost-effective measure to effectively reduce deaths, hospitalizations, and outpatient visits due to rotavirus disease in China.
自 2006 年以来，全球已有两种轮状病毒疫苗获得许可。在中国，仅有一种羔羊轮状病毒疫苗获得许可，还有几种新的轮状病毒疫苗正在开发中。有关在中国为儿童接种轮状病毒疫苗的预期健康影响和成本效益的数据将有助于决策者制定疫苗接种建议。
我们使用 Microsoft Excel 模型，比较了中国有无疫苗接种计划的轮状病毒疾病的国家卫生和经济负担。模型输入包括 2007 年轮状病毒结果（死亡、住院、门诊）负担和成本、预计疫苗效力、覆盖率和成本的数据。成本效益以每残疾调整生命年（DALY）的美元和美分/每挽救生命的美元衡量。
两剂轮状病毒疫苗接种计划可每年避免 3013 例（62%）死亡、194794 例（59%）住院和 1333356 例（51%）与轮状病毒疾病相关的门诊就诊。疫苗的医疗收支平衡价格为每剂 1.19 美元。从社会角度来看，在中国，疫苗价格为每剂 2.50 至 5 美元时，疫苗接种计划具有很高的成本效益，而疫苗价格为每剂 10 至 20 美元时也具有成本效益。
全国性的轮状病毒疫苗接种计划可能是一项有效减少中国轮状病毒疾病导致的死亡、住院和门诊就诊的具有成本效益的措施。
